Panacea Life Sciences Holdings annual ebitda
2014
2015
2016
2017
2018
2019
2020
2021
2022
Panacea Life Sciences Holdings EBITDA Growth & History (PLSH)
Panacea Life Sciences Holdings's calculated EBITDA was −$3.9M for fiscal 2022.
View full Panacea Life Sciences Holdings company overviewPanacea Life Sciences Holdings annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | −$3.9M | $278,831 | — |
| 2021 | 2021-12-31 | −$4.2M | −$634,142 | — |
| 2020 | 2020-12-31 | −$3.6M | $6.2M | — |
| 2019 | 2019-12-31 | −$9.8M | −$7.7M | — |
| 2018 | 2018-12-31 | −$2.0M | $1.0M | — |
| 2017 | 2017-12-31 | −$3.1M | −$1.5M | — |
| 2016 | 2016-12-31 | −$1.6M | −$1.2M | — |
| 2015 | 2015-12-31 | −$387,655 | $30,814 | — |
| 2014 | 2014-12-31 | −$418,469 | — | — |
Panacea Life Sciences Holdings quarterly ebitda
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2022 | 2022-12-31 | −$930,787 | $1.2M | — |
| Q3 2022 | 2022-09-30 | −$951,664 | −$476,801 | — |
| Q2 2022 | 2022-06-30 | −$814,757 | $133,640 | — |
| Q1 2022 | 2022-03-31 | −$1.2M | −$559,791 | — |
| Q4 2021 | 2021-12-31 | −$2.1M | −$2.0M | — |
| Q3 2021 | 2021-09-30 | −$474,863 | $2.0M | — |
| Q2 2021 | 2021-06-30 | −$948,397 | −$2.3M | — |
| Q1 2021 | 2021-03-31 | −$664,152 | $1.7M | — |
| Q4 2020 | 2020-12-31 | −$146,370 | $3.6M | — |
| Q3 2020 | 2020-09-30 | −$2.5M | −$702,502 | — |
| Q2 2020 | 2020-06-30 | $1.4M | $3.1M | — |
| Q1 2020 | 2020-03-31 | −$2.4M | $182,539 | — |
| Q4 2019 | 2019-12-31 | −$3.7M | −$3.3M | — |
| Q3 2019 | 2019-09-30 | −$1.8M | −$1.0M | — |
| Q2 2019 | 2019-06-30 | −$1.7M | −$1.4M | — |
| Q1 2019 | 2019-03-31 | −$2.5M | −$2.3M | — |
| Q3 2018 | 2018-09-30 | −$425,927 | −$192,560 | — |
| Q4 2016 | 2016-12-31 | −$747,433 | −$627,278 | — |
| Q3 2016 | 2016-09-30 | −$359,813 | −$257,636 | — |
| Q2 2016 | 2016-06-30 | −$260,873 | −$158,966 | — |
| Q1 2016 | 2016-03-31 | −$233,367 | −$169,951 | — |
| Q4 2015 | 2015-12-31 | −$120,155 | −$45,701 | — |
| Q3 2015 | 2015-09-30 | −$102,177 | −$85,512 | — |
| Q2 2015 | 2015-06-30 | −$101,907 | — | — |
| Q1 2015 | 2015-03-31 | −$63,416 | — | — |
| Q3 2014 | 2014-09-30 | −$74,454 | — | — |
| Q2 2014 | 2014-06-30 | −$16,665 | — | — |
Panacea Life Sciences Holdings ebitda trends
Over the last five reported fiscal years, Panacea Life Sciences Holdings's ebitda decreased from −$3.1M to −$3.9M, a change of −$849,039. The latest reported quarter, Q4 2022, shows −$930,787.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Panacea Life Sciences Holdings filings at SEC.gov ↗